Evaxion Biotech A/S (NASDAQ:EVAX) Upgraded by Zacks Investment Research to Buy

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 3 December, 2021 by The TZ Newswire Staff

Evaxion Biotech A/S (NASDAQ:EVAX) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com report

See also
- Next Article FY2022 Earnings Estimate for Konica Minolta, Inc. (OTCMKTS:KNCAY) Issued By Jefferies Financial Group
- Previous Article Traders say ATOM could eventually do an AVAX-like surge to $100
Editorial Calender

December 2021

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Nov Jan »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 3 December, 2021 by The TZ Newswire Staff

Evaxion Biotech A/S (NASDAQ:EVAX) Upgraded by Zacks Investment Research to Buy

See also

Editorial Calender

Recent Tags